Jiangsu Hengrui Pharma Delays Board Re-election, Extends Current Directors’ Terms
I'm PortAI, I can summarize articles.
Jiangsu Hengrui Pharmaceuticals Co., Ltd. has announced a delay in the re-election of its board of directors, which was originally set to occur before the term expiration on February 1, 2026. The current board members' terms will be extended to ensure stability and continuity in governance. The company assures that this delay will not affect normal operations and is working to expedite the re-election process. The latest analyst rating for the stock (HK:1276) is a Buy with a target price of HK$96.90.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments